Home › Companies › CARISMA THERAPEUTICS INC. › 2023-2024
At CARISMA THERAPEUTICS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 86 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 399 separate fund positions. On the most widely held item on that ballot — TO HOLD AN ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION. — CARISMA THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CARISMA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CARISMA THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 14, 2024: 4 items on CARISMA THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024: 2 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore CARISMA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CARISMA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John Hohneker, M.D. | 16,741,881 | -- | -- | 612,693 | 7,462,405 | 96% | Elected | — |
| Elect Director: Michael Torok | 16,023,508 | -- | -- | 1,331,066 | 7,462,405 | 92% | Elected | — |
| 2. Non-binding, advisory proposal on the compensation of the Company's named executive officers | 16,719,502 | 575,356 | 59,716 | -- | 7,462,405 | 97% | Approved | — |
| 3. Appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 24,389,393 | 172,754 | 254,832 | -- | -- | 99.2% | Approved | — |
Source: CARISMA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.
Each item below shows how the 86 asset managers that disclosed a CARISMA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders: John Hohneker, M.D.
CARISMA THERAPEUTICS INC.’s own tally for this item (“Elect Director: John Hohneker, M.D.”): 16,741,881 for, 612,693 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to the Company's Board of Directors as Class I directors for terms expiring at the 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 1,953,933 for, 46,971 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 874,810 | 0 | 0 | 0 | For |
| Vanguard | 739,243 | 0 | 0 | 0 | For |
| Fidelity | 42,618 | 0 | 0 | 19,448 | Mixed |
| Equitable | 55,719 | 0 | 0 | 0 | For |
| Charles Schwab | 48,125 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,121 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 0 | 0 | 27,523 | Withhold |
| Lincoln Financial | 22,700 | 0 | 0 | 0 | For |
| Invesco | 21,688 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,089 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 10,629 | 0 | 0 | 0 | For |
| Pacific Life | 10,524 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 10,213 | 0 | 0 | 0 | For |
| Voya | 9,948 | 0 | 0 | 0 | For |
| Northern Trust | 8,711 | 0 | 0 | 0 | For |
| Nationwide | 8,300 | 0 | 0 | 0 | For |
| John Hancock | 6,873 | 0 | 0 | 0 | For |
| ProShares | 4,353 | 0 | 0 | 0 | For |
| DWS | 4,111 | 0 | 0 | 0 | For |
| Principal | 3,409 | 0 | 0 | 0 | For |
| State Street | 2,785 | 0 | 0 | 0 | For |
| Calvert | 2,202 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,809 | 0 | 0 | 0 | For |
| TIAA | 1,555 | 0 | 0 | 0 | For |
| American Century | 1,080 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders: Michael Torok
CARISMA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Torok”): 16,023,508 for, 1,331,066 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to the Company's Board of Directors as Class I directors for terms expiring at the 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 1,903,607 for, 97,297 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 874,810 | 0 | 0 | 0 | For |
| Vanguard | 739,243 | 0 | 0 | 0 | For |
| Fidelity | 42,618 | 0 | 0 | 19,448 | Mixed |
| Equitable | 48,939 | 0 | 0 | 6,780 | Mixed |
| Charles Schwab | 48,125 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,121 | 0 | 0 | 0 | For |
| EA Series Trust | 27,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 22,700 | Withhold |
| Invesco | 21,688 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 15,089 | Withhold |
| Bridge Builder Trust | 10,629 | 0 | 0 | 0 | For |
| Pacific Life | 10,524 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 10,213 | 0 | 0 | 0 | For |
| Voya | 9,948 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 8,711 | Withhold |
| Nationwide | 0 | 0 | 0 | 8,300 | Withhold |
| John Hancock | 0 | 0 | 0 | 6,873 | Withhold |
| ProShares | 4,353 | 0 | 0 | 0 | For |
| DWS | 4,111 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 3,409 | Withhold |
| State Street | 0 | 0 | 0 | 2,785 | Withhold |
| Calvert | 0 | 0 | 0 | 2,202 | Withhold |
| T. Rowe Price | 1,809 | 0 | 0 | 0 | For |
| TIAA | 1,555 | 0 | 0 | 0 | For |
| American Century | 1,080 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: TO HOLD AN ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION.
CARISMA THERAPEUTICS INC.’s own tally for this item (“2. A non-binding, advisory proposal on the compensation of the Company's named executive officers”): 16,719,502 for, 575,356 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “A non-binding, advisory proposal on the compensation of the Company's named executive officers was approved.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 874,810 | 0 | 0 | 0 | For |
| Vanguard | 739,243 | 0 | 0 | 0 | For |
| Fidelity | 62,066 | 0 | 0 | 0 | For |
| Equitable | 55,719 | 0 | 0 | 0 | For |
| Charles Schwab | 48,125 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,121 | 0 | 0 | 0 | For |
| EA Series Trust | 27,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 22,700 | 0 | 0 | 0 | For |
| Invesco | 0 | 21,688 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 15,089 | 0 | 0 | Against |
| Bridge Builder Trust | 10,629 | 0 | 0 | 0 | For |
| Pacific Life | 10,524 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 10,213 | 0 | 0 | 0 | For |
| Voya | 9,948 | 0 | 0 | 0 | For |
| Northern Trust | 8,711 | 0 | 0 | 0 | For |
| Nationwide | 8,300 | 0 | 0 | 0 | For |
| John Hancock | 6,873 | 0 | 0 | 0 | For |
| ProShares | 4,353 | 0 | 0 | 0 | For |
| DWS | 4,111 | 0 | 0 | 0 | For |
| Principal | 3,409 | 0 | 0 | 0 | For |
| State Street | 2,785 | 0 | 0 | 0 | For |
| Calvert | 0 | 2,202 | 0 | 0 | Against |
| T. Rowe Price | 1,809 | 0 | 0 | 0 | For |
| TIAA | 1,555 | 0 | 0 | 0 | For |
| American Century | 0 | 1,080 | 0 | 0 | Against |
Fund voting reports, all 30 managers: 1,960,844 for, 40,060 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 526,967 | 0 | 0 | 0 | For |
| State Street | 321,701 | 0 | 0 | 0 | For |
| Northern Trust | 115,068 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 100,037 | 0 | 0 | 0 | For |
| FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 74,204 | 0 | 0 | 0 | For |
| Charles Schwab | 48,125 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 43,670 | 0 | 0 | 0 | For |
| Invesco | 0 | 31,755 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 25,873 | 0 | 0 | 0 | For |
| Fidelity | 23,047 | 0 | 0 | 0 | For |
| Rhumbline | 16,459 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 15,089 | 0 | 0 | Against |
| Vanguard | 13,322 | 0 | 0 | 0 | For |
| Prudential/PGIM | 12,957 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 11,000 | 0 | 0 | 0 | For |
| JPMorgan | 10,760 | 0 | 0 | 0 | For |
| Voya | 9,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 8,542 | 0 | 0 | 0 | For |
| Renaissance | 7,012 | 0 | 0 | 0 | For |
| John Hancock | 6,873 | 0 | 0 | 0 | For |
| AllianceBernstein | 6,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,712 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 5,552 | 0 | 0 | 0 | For |
| Nuveen | 4,469 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 3,863 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 1,422,930 for, 58,135 against, 183 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
CARISMA THERAPEUTICS INC.’s own tally for this item (“3. Appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 24,389,393 for, 172,754 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 1,973,381 for, 27,523 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 874,810 | 0 | 0 | 0 | For |
| Vanguard | 739,243 | 0 | 0 | 0 | For |
| Fidelity | 62,066 | 0 | 0 | 0 | For |
| Equitable | 55,719 | 0 | 0 | 0 | For |
| Charles Schwab | 48,125 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,121 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 27,523 | 0 | 0 | Against |
| Lincoln Financial | 22,700 | 0 | 0 | 0 | For |
| Invesco | 21,688 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,089 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 10,629 | 0 | 0 | 0 | For |
| Pacific Life | 10,524 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 10,213 | 0 | 0 | 0 | For |
| Voya | 9,948 | 0 | 0 | 0 | For |
| Northern Trust | 8,711 | 0 | 0 | 0 | For |
| Nationwide | 8,300 | 0 | 0 | 0 | For |
| John Hancock | 6,873 | 0 | 0 | 0 | For |
| ProShares | 4,353 | 0 | 0 | 0 | For |
| DWS | 4,111 | 0 | 0 | 0 | For |
| Principal | 3,409 | 0 | 0 | 0 | For |
| State Street | 2,785 | 0 | 0 | 0 | For |
| Calvert | 2,202 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,809 | 0 | 0 | 0 | For |
| TIAA | 1,555 | 0 | 0 | 0 | For |
| American Century | 1,080 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 41,542,744 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 2.11% |
| 2 | Vanguard | 1.78% |
| 3 | Fidelity | 0.15% |
| 4 | Equitable | 0.13% |
| 5 | Charles Schwab | 0.12% |
| 6 | QUANTITATIVE MASTER SERIES LLC | 0.11% |
| 7 | EA Series Trust | 0.07% |
| 8 | Lincoln Financial | 0.05% |
| 9 | Invesco | 0.05% |
| 10 | BRIDGEWAY FUNDS INC | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 1.27% |
| 2 | State Street | 0.77% |
| 3 | Northern Trust | 0.28% |
| 4 | MELLON INVESTMENTS Corp | 0.24% |
| 5 | FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 0.18% |
| 6 | Charles Schwab | 0.12% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.11% |
| 8 | Invesco | 0.08% |
| 9 | Connor, Clark & Lunn Investment Management Ltd. | 0.06% |
| 10 | Fidelity | 0.06% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| ModernaTX, Inc. | 12.18% | DEF14A |
| HealthCap VII L.P. | 8.18% | DEF14A |
| Entities affiliated with IPG | 6.53% | DEF14A |
| Longview Innovation Corp. | 6.53% | 13G |
| Wellington Life Sciences V GmbH & Co. KG | 5.53% | DEF14A |
| Regina Hodits, Ph.D. | 5.53% | DEF14A |
| SymBiosis II, LLC | 5.33% | DEF14A |
| AbbVie Biotechnology Ltd. | 4.47% | 13G |
| Steven Kelly | 2.75% | DEF14A |
| Michael Klichinsky, Pharm.D., Ph.D. | 1.88% | DEF14A |
Percentages above are of 41,542,744 shares outstanding, as reported by CARISMA THERAPEUTICS INC. on its Form 10-Q dated May 7, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CARISMA THERAPEUTICS INC.’s 10-Q dated May 7, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CARISMA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “CARISMA THERAPEUTICS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/carisma-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.